Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone844-445-5704
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.46 million
Profitability
Miscellaneous
Employees90
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
Xeris Pharmaceuticals (NASDAQ:XERS) Frequently Asked Questions
What is Xeris Pharmaceuticals' stock symbol?
Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS."
How were Xeris Pharmaceuticals' earnings last quarter?
Xeris Pharmaceuticals Inc (NASDAQ:XERS) posted its quarterly earnings results on Tuesday, August, 6th. The company reported ($1.28) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.94) by $0.34. The firm had revenue of $0.31 million for the quarter, compared to analysts' expectations of $0.20 million. Xeris Pharmaceuticals had a negative net margin of 4,876.50% and a negative return on equity of 107.65%. View Xeris Pharmaceuticals' Earnings History.
When is Xeris Pharmaceuticals' next earnings date?
What price target have analysts set for XERS?
2 equities research analysts have issued twelve-month price targets for Xeris Pharmaceuticals' stock. Their predictions range from $18.00 to $27.00. On average, they expect Xeris Pharmaceuticals' share price to reach $22.50 in the next twelve months. This suggests a possible upside of 117.4% from the stock's current price. View Analyst Price Targets for Xeris Pharmaceuticals.
What is the consensus analysts' recommendation for Xeris Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xeris Pharmaceuticals.
What are Wall Street analysts saying about Xeris Pharmaceuticals stock?
Here are some recent quotes from research analysts about Xeris Pharmaceuticals stock:
- 1. Mizuho analysts commented, "We applied a weighted average valuation methodology (DCF+EV/Sales) to derive our $27 PT. Our assumptions include: Launch of the glucagon rescue pen in the U.S. market in 4Q19, with unadjusted peak-sales of $454 mil in 2028 (current PoS: 90%)." (9/10/2019)
- 2. According to Zacks Investment Research, "Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company's proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based in Chicago, United States. " (1/12/2019)
Has Xeris Pharmaceuticals been receiving favorable news coverage?
News stories about XERS stock have trended negative this week, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Xeris Pharmaceuticals earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Xeris Pharmaceuticals.
Are investors shorting Xeris Pharmaceuticals?
Xeris Pharmaceuticals saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 1,876,700 shares, an increase of 9.0% from the July 31st total of 1,721,400 shares. Based on an average daily volume of 193,200 shares, the short-interest ratio is presently 9.7 days. Approximately 8.4% of the company's shares are short sold. View Xeris Pharmaceuticals' Current Options Chain.
Who are some of Xeris Pharmaceuticals' key competitors?
Some companies that are related to Xeris Pharmaceuticals include Innoviva (INVA), Spectrum Pharmaceuticals (SPPI), Y-mAbs Therapeutics (YMAB), Epizyme (EPZM), Athenex (ATNX), Amphastar Pharmaceuticals (AMPH), Esperion Therapeutics (ESPR), Zymeworks (ZYME), Dicerna Pharmaceuticals (DRNA), Axsome Therapeutics (AXSM), ArQule (ARQL), Amneal Pharmaceuticals (AMRX), Wave Life Sciences (WVE), Cara Therapeutics (CARA) and NextCure (NXTC).
What other stocks do shareholders of Xeris Pharmaceuticals own?
Who are Xeris Pharmaceuticals' key executives?
Xeris Pharmaceuticals' management team includes the folowing people:
- Mr. Paul R. Edick, Pres, CEO & Chairman (Age 63)
- Mr. Barry M. Deutsch, Chief Financial Officer (Age 54)
- Mr. John P. Shannon, Exec. VP & COO (Age 57)
- Dr. Steven J. Prestrelski, Co-Founder & Chief Scientific Officer (Age 55)
- Ms. Allison Wey, Sr. VP of Investor Relations & Corp. Communications
When did Xeris Pharmaceuticals IPO?
(XERS) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.
Who are Xeris Pharmaceuticals' major shareholders?
Xeris Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.93%), Vanguard Group Inc. (4.52%), Invesco Ltd. (3.71%), Bank of New York Mellon Corp (1.13%), Northern Trust Corp (0.92%) and Charles Schwab Investment Management Inc. (0.25%). Company insiders that own Xeris Pharmaceuticals stock include Beth Hecht, James E Flynn, Palmetto Partners, Ltd, Paul R Edick, Redmile Group, Llc and Steven Prestrelski. View Institutional Ownership Trends for Xeris Pharmaceuticals.
Which major investors are selling Xeris Pharmaceuticals stock?
XERS stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., BNP Paribas Arbitrage SA and Royal Bank of Canada. Company insiders that have sold Xeris Pharmaceuticals company stock in the last year include James E Flynn and Steven Prestrelski. View Insider Buying and Selling for Xeris Pharmaceuticals.
Which major investors are buying Xeris Pharmaceuticals stock?
XERS stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., Vanguard Group Inc., Wells Fargo & Company MN, IHT Wealth Management LLC, Charles Schwab Investment Management Inc., Susquehanna International Group LLP and Bank of New York Mellon Corp. Company insiders that have bought Xeris Pharmaceuticals stock in the last two years include Beth Hecht, James E Flynn, Palmetto Partners, Ltd, Paul R Edick and Redmile Group, Llc. View Insider Buying and Selling for Xeris Pharmaceuticals.
How do I buy shares of Xeris Pharmaceuticals?
Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Xeris Pharmaceuticals' stock price today?
One share of XERS stock can currently be purchased for approximately $10.35.
How big of a company is Xeris Pharmaceuticals?
Xeris Pharmaceuticals has a market capitalization of $279.32 million and generates $2.46 million in revenue each year. The company earns $-60,080,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis. Xeris Pharmaceuticals employs 90 workers across the globe.View Additional Information About Xeris Pharmaceuticals.
What is Xeris Pharmaceuticals' official website?
How can I contact Xeris Pharmaceuticals?
Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at 844-445-5704 or via email at [email protected]
MarketBeat Community Rating for Xeris Pharmaceuticals (NASDAQ XERS)
MarketBeat's community ratings are surveys of what our community members think about Xeris Pharmaceuticals and other stocks. Vote "Outperform" if you believe XERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
